Thomas Goddemeier

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna et al. · The Lancet · 2009 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +13

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study

U. Gatzemeier, Joachim von Pawel, Ihor Vynnychenko et al. · The Lancet Oncology · 2010 · 117 citations

Medicine, Oncology, Pharmacology +16

Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

Ágnes Ruzsa, Mehmet Şen, Mark D. Evans et al. · Investigational New Drugs · 2014 · 57 citations

Medicine, Oncology, Cancer Pharmacology +9

Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck

Jean‐Pascal Machiels, Marie‐Christine Kaminsky, Ulrich Keller et al. · Investigational New Drugs · 2013 · 38 citations

Medicine, Oncology, Pharmacology +14

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

Melinda L. Telli, Sara M. Tolaney, Geoffrey I. Shapiro et al. · npj Breast Cancer · 2022 · 38 citations · Full text

Medicine, Oncology, Pharmacology +15